6533b7d0fe1ef96bd125ae17
RESEARCH PRODUCT
Correlation between polymorphism of TYMS gene and toxicity response to treatment with 5-fluoruracil and capecitabine
Gabriella SchieraMaria Rita RicciardiStefano VitelloCarlo Maria Di LiegroAlessandra AmatoPatrizia ProiaGiuseppe MessinaItalia Di LiegroChiara Vergasubject
0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentlcsh:Medicinethymidylate synthasemedicine.disease_causeThymidylate synthaseArticlelcsh:QM1-695CapecitabineCorrelationCancer Genetics Polymorphisms Thymidylate synthase Toxicity03 medical and health sciences0302 clinical medicineInternal medicineGenotypeMedicineOrthopedics and Sports MedicinegeneticsGeneMolecular BiologyCancerChemotherapybiologybusiness.industrylcsh:RtoxicityCell Biologylcsh:Human anatomy030104 developmental biology030220 oncology & carcinogenesisToxicitybiology.proteinNeurology (clinical)businessCarcinogenesispolymorphismsmedicine.drugdescription
Tumorigenesis is a multiphasic process in which genetic alterations guide the progressive transformation in cancer cells1. In order to evaluate the possible correlation between some gene variants and the risk of the toxicity development onset, two of the polymorphisms of the thymidylate synthase (TYMS), rs34743033 (2R/3R) and rs16430 (DEL/INS) were investigated. We enrolled in our study 47 patients from the Hospital of Sicily. Our preliminary findings suggest that there could be a linkage between the genotypes discussed and the development of the toxicity following the chemotherapy treatment. These results need to be confirmed by further studies, however this short paper offers some initial insight into the relationships between genetic background and the better outcome for patients.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-08-04 |